Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Non Operating Income (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Non Operating Income readings, the most recent being -$2.1 million for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 208.91% to -$2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.4 million, a N/A change, with the full-year FY2025 number at -$3.4 million, changed N/A from a year prior.
  • Non Operating Income hit -$2.1 million in Q4 2025 for Fennec Pharmaceuticals, down from -$449000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.0 million in Q4 2024 to a low of -$2.1 million in Q4 2025.
  • Median Non Operating Income over the past 5 years was -$449000.0 (2025), compared with a mean of -$402894.7.
  • Biggest five-year swings in Non Operating Income: soared 2211.11% in 2021 and later plummeted 1483.33% in 2022.
  • Fennec Pharmaceuticals' Non Operating Income stood at -$12000.0 in 2021, then tumbled by 5916.67% to -$722000.0 in 2022, then decreased by 19.67% to -$864000.0 in 2023, then surged by 326.04% to $2.0 million in 2024, then tumbled by 208.91% to -$2.1 million in 2025.
  • The last three reported values for Non Operating Income were -$2.1 million (Q4 2025), -$449000.0 (Q3 2025), and -$420000.0 (Q2 2025) per Business Quant data.